HOMOCYSTINURIA

Homocystinuria — where the CBS genotype determines whether the patient responds to vitamin B6 therapy with near-normal outcomes, or requires lifelong methionine-restricted diet and betaine supplementation.

Whole genome sequencing identifies the specific CBS variant — distinguishing pyridoxine (B6)-responsive from non-responsive homocystinuria — the single most important prognostic and treatment distinction in this condition.

CLIA CertifiedCAP AccreditedISO 15189 Medical LabACMG ClassifiedHIPAA & GDPR100,000+ Genomes Sequenced

About this condition

Homocystinuria

Classical homocystinuria is an autosomal recessive disorder of methionine metabolism caused by deficiency of cystathionine β-synthase (CBS, chromosome 21q22.3). CBS catalyzes the condensation of homocysteine with serine to form cystathionine — the first step of the transsulfuration pathway. CBS deficiency causes accumulation of homocysteine and methionine in blood and tissues. Homocystinuria affects approximately 1 in 200,000-300,000 births worldwide, with higher prevalence in Ireland (~1 in 65,000) and Qatar (~1 in 1,800). Pyridoxine (vitamin B6) is a cofactor for CBS, and approximately 50% of patients have B6-responsive forms that retain partial CBS activity.

Untreated homocystinuria produces a recognizable clinical syndrome: ectopia lentis (lens dislocation — characteristically downward, distinguishing it from Marfan syndrome where lenses dislocate upward), Marfanoid skeletal features (tall stature, long limbs, pectus deformity, scoliosis), thromboembolism (the leading cause of mortality — elevated homocysteine promotes endothelial damage and coagulation activation), and intellectual disability (variable, ranging from normal intelligence to severe impairment). The thromboembolic risk is lifelong: stroke, pulmonary embolism, and deep vein thrombosis cause significant morbidity and mortality, particularly during surgery, pregnancy, or immobilization.

Treatment depends fundamentally on B6 responsiveness. B6-responsive patients (approximately 50%) are treated with high-dose pyridoxine (100-500mg/day), which enhances residual CBS activity and normalizes or near-normalizes plasma homocysteine levels — these patients have substantially better outcomes including preserved intellect, reduced thromboembolic risk, and often no need for dietary methionine restriction. B6-non-responsive patients require lifelong methionine-restricted diet, betaine supplementation (which provides an alternative route for homocysteine remethylation), folate, and B12. The distinction between responsive and non-responsive forms is the critical management decision and is determined by the specific CBS genotype.

Lens dislocation in homocystinuria is typically downward (inferonasal), while in Marfan syndrome it is upward (superotemporal). Any patient with lens dislocation should have plasma homocysteine measured — this single lab test distinguishes the two conditions.

Gene locus
CBS (21q22.3)

B6 responsiveness determines the entire treatment approach and long-term prognosis. The CBS genotype predicts responsiveness with high accuracy — enabling immediate treatment optimization rather than months of empirical trial.

B6-responsive CBS variants predict near-normal outcomes — non-responsive variants predict need for lifelong dietary restriction

The CBS variants p.Ile278Thr and p.Ala114Val are associated with B6-responsive homocystinuria and retain meaningful residual enzyme activity. Patients homozygous or compound heterozygous for these variants typically achieve biochemical normalization on pyridoxine therapy alone, with excellent long-term intellectual and vascular outcomes. In contrast, p.Gly307Ser (the most common Irish/European variant) is B6-non-responsive and requires lifelong methionine-restricted diet and betaine. Molecular genotyping provides immediate treatment stratification — rather than the 6-8 week empirical B6 trial that delays definitive management.

Surgical and anesthetic risk is dramatically elevated in undiagnosed homocystinuria — molecular diagnosis prevents perioperative catastrophe

Elevated homocysteine dramatically increases perioperative thromboembolic risk. Undiagnosed homocystinuria patients undergoing surgery — particularly orthopedic procedures, which involve immobilization — are at extreme risk for intraoperative or postoperative stroke, pulmonary embolism, or deep vein thrombosis. Several case reports document perioperative death in previously undiagnosed homocystinuria patients. Molecular diagnosis enables appropriate preoperative homocysteine-lowering therapy, perioperative anticoagulation, and avoidance of nitrous oxide anesthesia (which inhibits methionine synthase and acutely worsens homocysteine levels).

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks